PROMIS NEUROSCIENCES INC. Foreign Currency Transaction Gain (Loss), before Tax
PROMIS NEUROSCIENCES INC. (PMN) reported Foreign Currency Transaction Gain (Loss), before Tax of $1.82 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2025-03-31
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for the quarter ending 2023-12-31 was -$815.00, a 101.31% decline year-over-year.
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for the quarter ending 2023-09-30 was -$42.25K.
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for the quarter ending 2023-06-30 was $39.90K.
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for the quarter ending 2023-03-31 was $4.98K, a 95.65% decline year-over-year.
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was $1.82K.
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$305.41K.
- PROMIS NEUROSCIENCES INC. foreign currency transaction gain (loss), before tax for fiscal 2021 was -$85.07K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$815.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$43.07K derived: sum of 2 quarters · filed 2025-03-31 | -$3.17K derived: sum of 3 quarters · filed 2025-03-31 | $1.82K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$42.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.35K derived: sum of 2 quarters · filed 2024-11-14 | $2.63K 10-Q · filed 2024-11-14 | $64.87K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $39.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $44.88K 10-Q · filed 2024-08-08 | $107.13K derived: sum of 3 quarters · filed 2024-08-08 | -$9.49K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.98K 10-Q · filed 2024-05-14 | $67.23K derived: sum of 2 quarters · filed 2024-05-14 | -$49.39K derived: sum of 3 quarters · filed 2024-05-14 | -$415.13K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $62.24K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$54.37K derived: sum of 2 quarters · filed 2024-04-01 | -$420.11K derived: sum of 3 quarters · filed 2024-04-01 | -$305.41K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$116.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$482.36K derived: sum of 2 quarters · filed 2023-11-14 | -$367.65K 10-Q · filed 2023-11-14 | -$344.81K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$365.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$251.03K 10-Q · filed 2023-08-14 | -$228.19K derived: sum of 3 quarters · filed 2023-08-14 | -$432.77K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $114.71K 10-Q · filed 2023-05-15 | $137.54K derived: sum of 2 quarters · filed 2023-05-15 | -$67.03K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $22.84K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$181.74K derived: sum of 2 quarters · filed 2023-03-08 | -$85.07K 10-K · filed 2023-03-08 | |
| 2021-09-30 | -$204.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$107.91K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $96.67K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |